3-溴-2-乙氧基-6-甲基吡啶 | 717843-50-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-溴-2-乙氧基-6-甲基吡啶
• 英文名称: 3-Bromo-2-ethoxy-6-methylpyridine
• CAS: 717843-50-0
• 化学式: C₈H₁₀BrNO
• 分子量: 216.07
• InChiKey: GGKRLDWLBSDKEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

文献信息

• Substituted pyridoindoles as serotonin agonists and antagonists
  申请人：——

  公开号：US20040186094A1

  公开（公告）日：2004-09-23

  The present invention is directed to certain novel compounds represented by structural Formula (I) 1 or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 5 , R 6 , R 7 , R 8 , R 9 , X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

  本发明涉及一些新型化合物，其结构式表示为（I）或其药用盐形式，其中R1、R5、R6、R7、R8、R9、X、b、k和n以及虚线在此处描述。本发明还涉及包含这些新型化合物作为活性成分的药物配方，以及这些新型化合物及其配方在治疗某些疾病中的用途。本发明的化合物是5-羟色胺激动剂和拮抗剂，在控制或预防包括肥胖、焦虑、抑郁症、精神病、精神分裂症、睡眠障碍、性功能障碍、偏头痛、头痛相关疾病、社交恐惧症以及胃肠道疾病（如胃肠道运动功能障碍）等中枢神经系统疾病中有用。
• Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
  申请人：——

  公开号：US20040180875A1

  公开（公告）日：2004-09-16

  The present invention is directed to novel compounds represented by structural Formula (I): 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , R 4a , R 5 , R 6 , R 7 , R 8 , R 9 , and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT 2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.

  本发明涉及由结构式(I)表示的新化合物或其药学上可接受的盐，其中R1、R4a、R5、R6、R7、R8、R9和m在此被定义。本发明还涉及包含这些新化合物作为活性成分的制药配方以及在治疗某些中枢神经系统疾病中使用这些新化合物和它们的配方。本发明的化合物是血清素受体调节剂，特别是5HT2C受体激动剂和拮抗剂，并且在控制或预防中枢神经系统疾病，包括肥胖症、厌食症、暴食症、抑郁症、焦虑症、精神病、精神分裂症、偏头痛、成瘾行为、强迫症和性功能障碍方面是有用的。
• EP1581221A4
  申请人：——

  公开号：EP1581221A4

  公开（公告）日：2008-11-26
• SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1581221B1

  公开（公告）日：2011-05-18
• US6849619B2
  申请人：——

  公开号：US6849619B2

  公开（公告）日：2005-02-01